Sebastian Gidlöf1, Anna Wedell2, Claes Guthenberg3, Ulrika von Döbeln4, Anna Nordenström5. 1. Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden2Department of Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden. 2. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden4Center for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden. 3. Center for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden. 4. Center for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden5Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. 5. Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden4Center for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden6Department of Pediatric Endocrinology, Astrid Lindgren Children's Hospital, Ka.
Abstract
IMPORTANCE: Recent reports have questioned the rationale for neonatal screening for congenital adrenal hyperplasia (CAH) owing to low sensitivity in salt-wasting forms and a high rate of recall (ie, a positive finding resulting in a visit to a pediatrician and a second test) in preterm infants. OBJECTIVE: To determine the efficiency of the neonatal screening program for CAH in Sweden over time. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal prospective population-based study in Sweden. We assessed neonatal screening for CAH from January 1, 1986, through December 31, 2011, when 2 737 932 infants (99.8%) underwent testing. The CYP21A2 genotype was investigated in 219 cases with true-positive findings (94.8%). We investigated the screening outcomes for 231 patients who had true-positive findings, 43 with late diagnosis, and 1497 infants with false-positive findings. MAIN OUTCOMES AND MEASURES: Sensitivity of the screening for salt-wasting CAH. The most important secondary outcome measures were the positive predictive values and recall rates for full-term and preterm infants and sensitivity for milder forms of CAH. RESULTS: A total of 143 patients with salt-wasting CAH were identified; none were missed. The sensitivity was lower for milder forms of the disorder (P = .04), including 79.7% for simple virilizing forms and 32.4% for nonclassic forms. The positive predictive value was higher in full-term (25.1%) than preterm (1.4%) infants and correlated with gestational age (r = 0.98; P < .001). The recall rate in full-term infants (0.03%) was lower than that in preterm infants (0.57%) (P < .001). An analysis of previously reported results from other screening programs revealed that the sensitivity of the screening was negatively correlated with the duration of follow-up (P = .03). CONCLUSIONS AND RELEVANCE: Screening for CAH was highly effective in detecting the salt-wasting form and thereby reducing mortality. Additional late-onset cases of CAH were detected in childhood and adolescence, reducing the sensitivity for milder forms. The positive predictive value was high despite a low recall rate in full-term infants. Further improvements are necessary to increase the effectiveness of screening among preterm infants.
IMPORTANCE: Recent reports have questioned the rationale for neonatal screening for congenital adrenal hyperplasia (CAH) owing to low sensitivity in salt-wasting forms and a high rate of recall (ie, a positive finding resulting in a visit to a pediatrician and a second test) in preterm infants. OBJECTIVE: To determine the efficiency of the neonatal screening program for CAH in Sweden over time. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal prospective population-based study in Sweden. We assessed neonatal screening for CAH from January 1, 1986, through December 31, 2011, when 2 737 932 infants (99.8%) underwent testing. The CYP21A2 genotype was investigated in 219 cases with true-positive findings (94.8%). We investigated the screening outcomes for 231 patients who had true-positive findings, 43 with late diagnosis, and 1497 infants with false-positive findings. MAIN OUTCOMES AND MEASURES: Sensitivity of the screening for salt-wasting CAH. The most important secondary outcome measures were the positive predictive values and recall rates for full-term and preterm infants and sensitivity for milder forms of CAH. RESULTS: A total of 143 patients with salt-wasting CAH were identified; none were missed. The sensitivity was lower for milder forms of the disorder (P = .04), including 79.7% for simple virilizing forms and 32.4% for nonclassic forms. The positive predictive value was higher in full-term (25.1%) than preterm (1.4%) infants and correlated with gestational age (r = 0.98; P < .001). The recall rate in full-term infants (0.03%) was lower than that in preterm infants (0.57%) (P < .001). An analysis of previously reported results from other screening programs revealed that the sensitivity of the screening was negatively correlated with the duration of follow-up (P = .03). CONCLUSIONS AND RELEVANCE: Screening for CAH was highly effective in detecting the salt-wasting form and thereby reducing mortality. Additional late-onset cases of CAH were detected in childhood and adolescence, reducing the sensitivity for milder forms. The positive predictive value was high despite a low recall rate in full-term infants. Further improvements are necessary to increase the effectiveness of screening among preterm infants.
Authors: Patrice K Held; Stuart K Shapira; Cynthia F Hinton; Elizabeth Jones; W Harry Hannon; Jelili Ojodu Journal: Mol Genet Metab Date: 2015-08-12 Impact factor: 4.797
Authors: Alan D Bolnick; Rani Fritz; Chandni Jain; Leena Kadam; Jay M Bolnick; Brian A Kilburn; Manvinder Singh; Michael P Diamond; Sascha Drewlo; D Randall Armant Journal: Reprod Sci Date: 2016-02-25 Impact factor: 3.060
Authors: Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White Journal: Endocr Rev Date: 2022-01-12 Impact factor: 19.871
Authors: Zhuoguang Li; Lianjing Huang; Caiqi Du; Cai Zhang; Mini Zhang; Yan Liang; Xiaoping Luo Journal: Front Endocrinol (Lausanne) Date: 2021-04-23 Impact factor: 5.555